PODD
Insulet Corporation
$138.97
▼ 4.7%Updated Today 7:15 PM ET
▼ Down 51.7% over the last 12 months
Market Cap
$10.10B
P/E
33.29x
Forward P/E (est.)
42.17x
ROE
17.4%
Revenue Growth
31.9%
EPS Growth
-21.1%
Profit Margin
10.4%
FCF Yield
1.8%
Debt / Equity
0.63x
ROIC
14.0%
Interest Coverage
13.09x
Current Ratio
2.49x
Dividend Yield
—
Implied Growth (rev. DCF)
5.1%
Rating Score
52/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what PODD's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. PODD trades near $138.97, below its 50-day average ($166.25) and 200-day average ($257.41). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 51 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. PODD's is $6.46 (~4.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month PODD found buyers near $140.63 (support) and sellers near $161.35 (resistance); its 52-week range is $140.63–$354.88. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Insulet Corporation (PODD) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $10.10B.
In its latest reported year it generated about $2.71B in revenue and $247.10M in net profit.
Our model rates PODD Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
25.3%
Revenue moved from $1.10B in 2021 to $2.71B in 2025, a 25.3% compound annual growth rate. The most recent year grew a strong 31.9% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
71.6%
Operating Margin
17.5%
Net Margin
9.1%
ROE
17.4%
Insulet Corporation keeps about 10.4% of each sales dollar as net profit, with a 71.6% gross margin and 17.5% operating margin. Return on equity is 17.4% and return on invested capital about 14.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$1.40B
Net Debt
$541.20M
Net Debt / EBITDA
1.14x
Debt / Equity
0.63x
Leverage: debt-to-equity is 0.6x, and operating profit covers interest about 13.1x, with a current ratio of 2.5x. That is a moderate, manageable debt load for most businesses. It carries roughly $1.40B of total debt against $856.60M of cash.
Operating CF
$569.30M
Free Cash Flow
$377.70M
FCF Margin
13.9%
In the latest year Insulet Corporation produced about $569.30M of operating cash flow and $377.70M of free cash flow after capital spending. That is a free-cash-flow yield of about 1.8% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
33.29x
P/S
3.77x
P/B
13.02x
EV / EBITDA
19.09x
PODD trades at 33.3x trailing earnings (about 42.2x on estimated forward earnings), 3.8x sales, and 13.0x book value. Reverse-engineering today's price implies the market expects roughly 5.1% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How PODD stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), PODD ranks #31 of 59 by our overall rating. It trades at a premium versus the sector on earnings (33.3x P/E vs. 25.4x median) with a higher return on equity (17.4% vs. 14.9%) and faster revenue growth (31.9% vs. 7.9%).
P/E vs sector
33.3x
median 25.4x
ROE vs sector
17.4%
median 14.9%
Growth vs sector
31.9%
median 7.9%
Sector rank
#31
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$282.03 – $465.35
vs. $138.97 today · expected CAGR 15% – 27%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.57B | $4.72B | $6.23B | $8.22B | $10.85B |
| Net income | $321.72M | $424.67M | $560.57M | $739.95M | $976.74M |
| EPS | $4.64 | $6.13 | $8.09 | $10.68 | $14.10 |
| Share price (low) | $92.90 | $122.62 | $161.86 | $213.66 | $282.03 |
| Share price (high) | $153.28 | $202.33 | $267.07 | $352.54 | $465.35 |
| CAGR (low–high) | -33% / 10% | -6% / 21% | 5% / 24% | 11% / 26% | 15% / 27% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for PODD:
- Revenue is growing 31.9% a year, a sign of real demand.
- Strong return on equity (17.4%) shows capital is put to work well.
The case against PODD:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 33.3x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Insulet Corporation is a large-cap health care business still growing nicely, with modest profitability, and a sound balance sheet. It trades at 33.3x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.